| Briarwood Behavioral Health Pllc | |
|
8680 Gratiot Rd Ste A Saginaw MI 48609-4885 | |
| (989) 272-4346 | |
| Not Available |
| Full Name | Briarwood Behavioral Health Pllc |
|---|---|
| Speciality | Social Worker |
| Location | 8680 Gratiot Rd Ste A, Saginaw, Michigan |
| Authorized Official Name and Position | Amy Lemke (OWNER / AUTHORIZED OFFICIAL) |
| Authorized Official Contact | 9892135960 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Briarwood Behavioral Health Pllc 801 Joe Mann Blvd Ste P-6 Midland MI 48642-8900 Ph: () - | Briarwood Behavioral Health Pllc 8680 Gratiot Rd Ste A Saginaw MI 48609-4885 Ph: (989) 272-4346 |
| NPI Number | 1083074181 |
|---|---|
| Provider Enumeration Date | 03/02/2016 |
| Last Update Date | 10/11/2023 |
| Certification Date | 10/11/2023 |
| Medicare PECOS PAC ID | 6406155001 |
|---|---|
| Medicare Enrollment ID | O20160503002381 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083074181 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 6801085271 (Michigan) | Primary |
| Provider Name | Amy J Lemke |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1528014719 PECOS PAC ID: 0143225938 Enrollment ID: I20060929000266 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
| Provider Name | Jennifer Ordway |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588253819 PECOS PAC ID: 6406265529 Enrollment ID: I20210430002432 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
| Provider Name | Taylor Anne Steinbauer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1306222666 PECOS PAC ID: 9830544741 Enrollment ID: I20231012003187 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
| Provider Name | Barbara Haire |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1417408378 PECOS PAC ID: 2163870395 Enrollment ID: I20231129001687 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
› Verified 1 days ago
Manc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4705 Towne Ctr, Ste. 201, Saginaw, MI 48604 Phone: 989-799-2770 Fax: 989-799-2737 | |
Cope Personal Developmental Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 S Jefferson Ave Ste 104, Saginaw, MI 48607 Phone: 989-752-6319 Fax: 989-752-0895 | |
Mind Body- Eft Thearpy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2438 Gatesboro Dr W, Saginaw, MI 48603 Phone: 989-274-4006 | |
Dahlia Therapy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3854 Dale Rd, Saginaw, MI 48603 Phone: 989-891-7854 | |
Saginaw Psychological Services Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2100 Hemmeter Rd, Saginaw, MI 48603 Phone: 989-799-2100 Fax: 989-799-2637 | |
Saginaw Psychological Services Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2100 Hemmeter Rd, Saginaw, MI 48603 Phone: 989-799-2100 Fax: 989-799-2637 | |
Mind Body-eft Therapy Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2438 Gatesboro Dr W, Saginaw, MI 48603 Phone: 989-274-4006 |